Abeona Therapeutics (ABEO) Equity Average (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Equity Average data on record, last reported at $167.4 million in Q3 2025.

  • For Q3 2025, Equity Average rose 181.32% year-over-year to $167.4 million; the TTM value through Sep 2025 reached $167.4 million, up 181.32%, while the annual FY2024 figure was $29.4 million, 41.53% up from the prior year.
  • Equity Average reached $167.4 million in Q3 2025 per ABEO's latest filing, up from $102.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $167.4 million in Q3 2025 and bottomed at $3.0 million in Q1 2024.
  • Average Equity Average over 5 years is $49.3 million, with a median of $32.2 million recorded in 2024.
  • Peak YoY movement for Equity Average: crashed 86.93% in 2024, then surged 1336.96% in 2025.
  • A 5-year view of Equity Average shows it stood at $61.1 million in 2021, then tumbled by 67.93% to $19.6 million in 2022, then decreased by 5.87% to $18.4 million in 2023, then surged by 143.61% to $44.9 million in 2024, then soared by 272.82% to $167.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $167.4 million in Q3 2025, $102.5 million in Q2 2025, and $42.7 million in Q1 2025.